Calidi (CLDI) Biotherapeutics presented new data on its first therapeutic candidate from its RedTail platform, CLD-401, at the Society of Immunotherapy for Cancer, SITC, Annual Meeting. “Our latest data demonstrate that in our syngeneic murine models, our RedTail platform is protected from immune clearance after systemic administration and can find and specifically replicate in tumor cells at metastatic sites,” said Antonio Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. “The data also demonstrate that the platform can effectively express genetic medicines at the tumor site in concentrations that are similar to what is achievable with localized dosing while avoiding systemic exposure.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDI:
- Calidi Biotherapeutics Sells Majority Stake in Nova Cell
- Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting
- Calidi Biotherapeutics Forms New Advisory Board
- Calidi announces formation of its Scientific Advisory Board
- Calidi Biotherapeutics Streamlines Leadership with Role Elimination